Bellerophon Therapeutics, Inc.
BLPH
BLPH was delisted on the 13th of October, 2023.
23 hedge funds and large institutions have $825K invested in Bellerophon Therapeutics, Inc. in 2023 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 6 increasing their positions, 2 reducing their positions, and 7 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 2
57% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 7
21% more funds holding
Funds holding: 19 → 23 (+4)
97% less capital invested
Capital invested by funds: $27.9M → $825K (-$27.1M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $1K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
+$1.71M |
| 2 |
Two Sigma Investments
New York
|
+$669K |
| 3 |
BlackRock
New York
|
+$216K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
+$191K |
| 5 |
VF
Virtu Financial
New York
|
+$167K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$7.34M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
-$7.05M |
| 3 |
Morgan Stanley
New York
|
-$5.81M |
| 4 |
Renaissance Technologies
New York
|
-$596K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$107K |
BLPH Hedge Fund Activity: Q2 2023 in Review
23 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Bellerophon Therapeutics, Inc. (BLPH) for Q2 2023, worth a combined $825K — down 97% from $27.9M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new BLPH positions and 7 closed out — a net gain of 4 holders — while 6 added to existing stakes and 2 trimmed.
The largest buyer was Acadian Asset Management, opening a new position worth an estimated $1.71M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $7.34M sold.
- 23 institutional investors held Bellerophon Therapeutics, Inc. (BLPH) as of Q2 2023, up from 19 in Q1 2023.
- Funds reported $825K of Bellerophon Therapeutics, Inc. stock for Q2 2023, down 97% quarter-over-quarter.
- 11 funds opened new Bellerophon Therapeutics, Inc. positions in Q2 2023 and 7 closed out, a net change of +4 holders.
- The largest Bellerophon Therapeutics, Inc. buyer in Q2 2023 was Acadian Asset Management, an estimated $1.71M added.
- The largest Bellerophon Therapeutics, Inc. seller in Q2 2023 was Perceptive Advisors, an estimated $7.34M sold.
Based on aggregated 13F filings for Q2 2023.